Skip to main content
OpenTrials
Completed

NCT Number: NCT02850029

An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey

This is an international observational cohort study on current aminoglycoside practices in intensive care units. Clinical and demographic data, dosing and therapeutic drug monitoring data will be collected during the first week of aminoglycoside (tobramycin, amikacin or gentamicin) administration in different countries over a year. A minimum of ten consecutive patients will be enrolled at each site.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Underdosing of Aminoglycosides Critical Illness Disease Attributes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Royal Brisbane Women's Hospital, Brisbane, Queensland, Australia

Loading trial locations.

About this study

Aminoglycosides are commonly used antibiotics for difficult to treat infections. However, aminoglycoside administration varies widely among countries. The aim of this multicenter observational study is to provide up-to-date and comprehensive descriptive data on current aminoglycoside (tobramycin, amikacin or gentamicin) use in a large cohort of critically ill patients in different countries. The benefits expected from this study are a better understanding of worldwide aminoglycoside prescription variability in critically ill patients and to determine the risk factors of inadequate aminoglycoside dosing regimens.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old
  • Intensive care unit patients
  • Receiving aminoglycoside therapy for a sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock

Exclusion criteria

  • Aged < 18 years of age
  • Previous inclusion in the study

Treatment and study plan

Observational study, no intervention

Other

Primary outcomes

  1. Aminoglycoside current practices descriptive data in intensive care units

    Time frame: Seven first days of aminoglycoside therapy

Secondary outcomes

  1. Aminoglycoside dosing regimens

    Time frame: Seven first days of aminoglycoside therapy

  2. Aminoglycoside therapy duration

    Time frame: Seven first days of aminoglycoside therapy

  3. Aminoglycoside therapeutic drug monitoring

    Time frame: Seven first days of aminoglycoside therapy

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jul 29, 2016
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.